So far, we have identified a gene, ECI2, for which knockdown inhibited prostate cancer cell proliferation and in addition suppressed expression of CDC6. Elevated expression of CDC6 is associated with poor patient outcome. This evidence concerns the gene CDC6 and prostate carcinoma.